Cargando…
Screening for onconeural antibodies in neuromyelitis optica spectrum disorders
BACKGROUND: Some so-called “non-classical” paraneoplastic neurological syndromes (PNS), namely optic neuritis and myelitis, clinically overlap with neuromyelitis optica spectrum disorders (NMOSD), and conversely, in cancer-associated NMOSD, a paraneoplastic etiology has been suggested in rare cases....
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5223419/ https://www.ncbi.nlm.nih.gov/pubmed/28068933 http://dx.doi.org/10.1186/s12883-016-0779-9 |
_version_ | 1782493167710371840 |
---|---|
author | Berger, Benjamin Hottenrott, Tilman Rauer, Sebastian Stich, Oliver |
author_facet | Berger, Benjamin Hottenrott, Tilman Rauer, Sebastian Stich, Oliver |
author_sort | Berger, Benjamin |
collection | PubMed |
description | BACKGROUND: Some so-called “non-classical” paraneoplastic neurological syndromes (PNS), namely optic neuritis and myelitis, clinically overlap with neuromyelitis optica spectrum disorders (NMOSD), and conversely, in cancer-associated NMOSD, a paraneoplastic etiology has been suggested in rare cases. Therefore, we retrospectively investigated the prevalence of onconeural antibodies, which are highly predictive for a paraneoplastic etiology, and the prevalence of malignancies in NMOSD patients. METHODS: We retrospectively screened 23 consecutive patients from our clinic with NMOSD (13 were anti-aquaporin-4 [AQP4] antibody positive, 10 were AQP4 negative) for onconeural antibodies using an immunoblot. RESULTS: All patients were negative for a broad spectrum of antibodies targeting intracellular onconeural antigens (Hu, Yo, Ri, CV2/CRMP5, Ma1, Ma2, Zic4, SOX1, Tr, and amphiphysin). Notably, only two patients had a malignancy. However, neoplastic entities (astrocytic brain tumor and acute myeloid leukemia) were not typical for PNS. CONCLUSIONS: Our data suggest that there is no need to routinely screen anti-AQP4 antibody positive NMOSD patients with a typical presentation for onconeural antibodies. Furthermore, absence of these antibodies in NMOSD, which is typically non-paraneoplastic, confirms their high specificity for PNS. |
format | Online Article Text |
id | pubmed-5223419 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-52234192017-01-11 Screening for onconeural antibodies in neuromyelitis optica spectrum disorders Berger, Benjamin Hottenrott, Tilman Rauer, Sebastian Stich, Oliver BMC Neurol Research Article BACKGROUND: Some so-called “non-classical” paraneoplastic neurological syndromes (PNS), namely optic neuritis and myelitis, clinically overlap with neuromyelitis optica spectrum disorders (NMOSD), and conversely, in cancer-associated NMOSD, a paraneoplastic etiology has been suggested in rare cases. Therefore, we retrospectively investigated the prevalence of onconeural antibodies, which are highly predictive for a paraneoplastic etiology, and the prevalence of malignancies in NMOSD patients. METHODS: We retrospectively screened 23 consecutive patients from our clinic with NMOSD (13 were anti-aquaporin-4 [AQP4] antibody positive, 10 were AQP4 negative) for onconeural antibodies using an immunoblot. RESULTS: All patients were negative for a broad spectrum of antibodies targeting intracellular onconeural antigens (Hu, Yo, Ri, CV2/CRMP5, Ma1, Ma2, Zic4, SOX1, Tr, and amphiphysin). Notably, only two patients had a malignancy. However, neoplastic entities (astrocytic brain tumor and acute myeloid leukemia) were not typical for PNS. CONCLUSIONS: Our data suggest that there is no need to routinely screen anti-AQP4 antibody positive NMOSD patients with a typical presentation for onconeural antibodies. Furthermore, absence of these antibodies in NMOSD, which is typically non-paraneoplastic, confirms their high specificity for PNS. BioMed Central 2017-01-10 /pmc/articles/PMC5223419/ /pubmed/28068933 http://dx.doi.org/10.1186/s12883-016-0779-9 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Berger, Benjamin Hottenrott, Tilman Rauer, Sebastian Stich, Oliver Screening for onconeural antibodies in neuromyelitis optica spectrum disorders |
title | Screening for onconeural antibodies in neuromyelitis optica spectrum disorders |
title_full | Screening for onconeural antibodies in neuromyelitis optica spectrum disorders |
title_fullStr | Screening for onconeural antibodies in neuromyelitis optica spectrum disorders |
title_full_unstemmed | Screening for onconeural antibodies in neuromyelitis optica spectrum disorders |
title_short | Screening for onconeural antibodies in neuromyelitis optica spectrum disorders |
title_sort | screening for onconeural antibodies in neuromyelitis optica spectrum disorders |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5223419/ https://www.ncbi.nlm.nih.gov/pubmed/28068933 http://dx.doi.org/10.1186/s12883-016-0779-9 |
work_keys_str_mv | AT bergerbenjamin screeningforonconeuralantibodiesinneuromyelitisopticaspectrumdisorders AT hottenrotttilman screeningforonconeuralantibodiesinneuromyelitisopticaspectrumdisorders AT rauersebastian screeningforonconeuralantibodiesinneuromyelitisopticaspectrumdisorders AT sticholiver screeningforonconeuralantibodiesinneuromyelitisopticaspectrumdisorders |